NeuBase Therapeutics (STU:O7P) Total Liabilities : €8.89 Mil (As of Sep. 2023)

View and export this data going back to 2019. Start your Free Trial

What is NeuBase Therapeutics Total Liabilities?

NeuBase Therapeutics's Total Liabilities for the quarter that ended in Sep. 2023 was €8.89 Mil.

NeuBase Therapeutics's quarterly Total Liabilities increased from Mar. 2023 (€6.55 Mil) to Jun. 2023 (€10.23 Mil) but then declined from Jun. 2023 (€10.23 Mil) to Sep. 2023 (€8.89 Mil).

NeuBase Therapeutics's annual Total Liabilities increased from Sep. 2019 (€2.27 Mil) to Sep. 2020 (€2.67 Mil) and increased from Sep. 2020 (€2.67 Mil) to Sep. 2021 (€8.58 Mil).

NeuBase Therapeutics Total Liabilities Historical Data

The historical data trend for NeuBase Therapeutics's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NeuBase Therapeutics Total Liabilities Chart

NeuBase Therapeutics Annual Data

Trend

Sep12

Sep13

Sep14

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Total Liabilities

Get a 7-Day Free Trial

4.27

0.25

2.27

2.67

8.58

NeuBase Therapeutics Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Total Liabilities	Get a 7-Day Free Trial															9.60	6.95	6.55	10.23	8.89

NeuBase Therapeutics Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

NeuBase Therapeutics's Total Liabilities for the fiscal year that ended in Sep. 2021 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	3.565	+	(5.018	+	8.8817841970013E-16
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	8.58

Total Liabilities	=	Total Assets (A: Sep. 2021 )	-	Total Equity (A: Sep. 2021 )
	=	54.543	-	45.96
	=	8.58

NeuBase Therapeutics's Total Liabilities for the quarter that ended in Sep. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	4.357	+	(4.529	+	0.0010000000000003
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	8.89

Total Liabilities	=	Total Assets (Q: Sep. 2023 )	-	Total Equity (Q: Sep. 2023 )
	=	17.448	-	8.561
	=	8.89

NeuBase Therapeutics Total Liabilities Related Terms

Thank you for viewing the detailed overview of NeuBase Therapeutics's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

NeuBase Therapeutics (STU:O7P) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NeuBase Therapeutics Inc (STU:O7P) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

NBSE:USA O7P:Germany

Address

350 Technology Drive, Suite 421, Pittsburgh, PA, USA, 15219

Website

https://www.neubasetherapeutics.com

NeuBase Therapeutics Inc is a pre-clinical stage biopharmaceutical company. It is engaged in the development of gene silencing therapies with its synthetic antisense oligonucleotides. Its Patrol platform is focused on the development of drugs for rare genetic diseases such as Huntington's Disease, Myotonic Dystrophy and Familial Parkinson's Disease among others.

NeuBase Therapeutics (STU:O7P) Headlines

No Headlines